Vepar5
- The Committee for Medicinal Products for Human Use of the European Medicines Agency, at its most recent meeting, recommended approval of eight new medicines.
This includes Eli Lilly's (NYSE:LLY) Ebglyss (lebrikizumab), for moderate-to-severe atopic dermatitis; Novartis' (NYSE:NVS) Finlee (dabrafenib) for glioma; a type of brain cancer; Daiichi Sankyo's (OTCPK:DSKYF) (OTCPK:DSNKY) Vanflyta (quizartinib), for the treatment of adult patients with diagnosed acute myeloid leukemia, and Ascendis Pharma's (ASND) Yorvipath (palopegteriparatide), a parathyroid hormone replacement therapy.
Positive opinions were also reached on UCB's (OTCPK:UCBJY) Zilbrysq (zilucoplan) for the treatment of generalized myasthenia gravis; a flu vaccine from Seqirus; Proveca Pharma's Aqumeldi (enalapril maleate) for heart failure in pediatric population; and Santen Pharmaceutical's Catiolanze (latanoprost) for the reduction of intraocular pressure.
More on Lilly, Ascendis, and Novartis
- Eli Lilly: A Potential Game Changer For Weight Management And Cardiovascular Health
- Ascendis Pharma: Revenue Promise Meets Cash Flow Challenge
- Sandoz to commercialize biosimilar to J&J blockbuster drug Stelara
- Sell Eli Lilly And Buy This Coiled-Spring Dividend Aristocrat Instead
- Ascendis wins EU backing for hormone replacement therapy